TP53 and colorectal carcinoma: In our first use case, we promped AI-HOPE with the question: “Compare TP53 mutations in early-stage versus late-stage colorectal cancer.” The agent recommended conducting a case-control study, comparing TP53 mutation frequency between early-stage (Stage I/II) and late-stage (Stage III/IV) CRC patients.